RS61586B1 - Anti-tfr antitela i njihova upotreba u lečenju proliferativnih i zapaljenjskih poremećaja - Google Patents
Anti-tfr antitela i njihova upotreba u lečenju proliferativnih i zapaljenjskih poremećajaInfo
- Publication number
- RS61586B1 RS61586B1 RS20210280A RSP20210280A RS61586B1 RS 61586 B1 RS61586 B1 RS 61586B1 RS 20210280 A RS20210280 A RS 20210280A RS P20210280 A RSP20210280 A RS P20210280A RS 61586 B1 RS61586 B1 RS 61586B1
- Authority
- RS
- Serbia
- Prior art keywords
- antibody
- seq
- tfr
- protein
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306192 | 2015-07-22 | ||
| PCT/EP2016/067465 WO2017013230A1 (en) | 2015-07-22 | 2016-07-21 | ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS |
| EP16744353.0A EP3325509B1 (en) | 2015-07-22 | 2016-07-21 | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61586B1 true RS61586B1 (sr) | 2021-04-29 |
Family
ID=53776520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210280A RS61586B1 (sr) | 2015-07-22 | 2016-07-21 | Anti-tfr antitela i njihova upotreba u lečenju proliferativnih i zapaljenjskih poremećaja |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11230605B2 (https=) |
| EP (1) | EP3325509B1 (https=) |
| JP (1) | JP6858185B2 (https=) |
| KR (1) | KR102690998B1 (https=) |
| CN (1) | CN107849136B (https=) |
| AU (1) | AU2016296321B2 (https=) |
| CA (1) | CA2992509C (https=) |
| CY (1) | CY1123941T1 (https=) |
| DK (1) | DK3325509T3 (https=) |
| ES (1) | ES2860988T3 (https=) |
| HR (1) | HRP20210393T1 (https=) |
| HU (1) | HUE053296T2 (https=) |
| IL (1) | IL257065B (https=) |
| LT (1) | LT3325509T (https=) |
| MX (1) | MX2018000569A (https=) |
| PL (1) | PL3325509T3 (https=) |
| PT (1) | PT3325509T (https=) |
| RS (1) | RS61586B1 (https=) |
| RU (1) | RU2737637C2 (https=) |
| SI (1) | SI3325509T1 (https=) |
| SM (1) | SMT202100134T1 (https=) |
| WO (1) | WO2017013230A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017023862A2 (pt) | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| FR3062213B1 (fr) | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2021092482A1 (en) | 2019-11-06 | 2021-05-14 | The Regents Of The University Of California | Compositions and methods for transferrin receptor 1 targeting |
| CN115427059A (zh) * | 2020-01-31 | 2022-12-02 | 达因疗法公司 | 抗转铁蛋白受体（tfr）抗体及其用途 |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP4396231A1 (en) | 2021-09-01 | 2024-07-10 | Biogen MA Inc. | Anti-transferrin receptor antibodies and uses thereof |
| WO2023039611A2 (en) * | 2021-09-13 | 2023-03-16 | The Board Of Regents Of The University Of Texas System | Tfr antigen binding proteins and uses thereof |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| KR20250114322A (ko) * | 2022-12-02 | 2025-07-29 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-tfr1 항체 및 이의 용도 |
| AR132194A1 (es) | 2023-03-24 | 2025-06-04 | Denali Therapeutics Inc | PROTEÍNAS DIRIGIDAS A Ab Y MÉTODOS DE USO |
| EP4477236A1 (en) | 2023-06-14 | 2024-12-18 | Inatherys | Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics |
| WO2025090898A1 (en) * | 2023-10-26 | 2025-05-01 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof cross reference to related applications |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434156A (en) | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
| HU230769B1 (hu) * | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| WO2005011082A2 (en) | 2003-07-23 | 2005-02-03 | Univeral Infusion Technology | Drive motor transmission system |
| WO2005111082A1 (en) * | 2004-04-30 | 2005-11-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-tfr antibody. |
| KR101295139B1 (ko) * | 2004-06-07 | 2013-08-12 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | 트랜스페린 리셉터 항체 |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| FR2953841B1 (fr) * | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| JP2015524816A (ja) * | 2012-08-02 | 2015-08-27 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用 |
| PL2918603T3 (pl) * | 2012-11-08 | 2019-01-31 | University Of Miyazaki | Przeciwciało zdolne do specyficznego rozpoznawania receptora transferyny |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
-
2016
- 2016-07-21 PT PT167443530T patent/PT3325509T/pt unknown
- 2016-07-21 CA CA2992509A patent/CA2992509C/en active Active
- 2016-07-21 KR KR1020187004745A patent/KR102690998B1/ko active Active
- 2016-07-21 PL PL16744353T patent/PL3325509T3/pl unknown
- 2016-07-21 EP EP16744353.0A patent/EP3325509B1/en active Active
- 2016-07-21 HU HUE16744353A patent/HUE053296T2/hu unknown
- 2016-07-21 JP JP2018522867A patent/JP6858185B2/ja active Active
- 2016-07-21 MX MX2018000569A patent/MX2018000569A/es unknown
- 2016-07-21 SI SI201631117T patent/SI3325509T1/sl unknown
- 2016-07-21 LT LTEP16744353.0T patent/LT3325509T/lt unknown
- 2016-07-21 AU AU2016296321A patent/AU2016296321B2/en active Active
- 2016-07-21 IL IL257065A patent/IL257065B/en unknown
- 2016-07-21 SM SM20210134T patent/SMT202100134T1/it unknown
- 2016-07-21 WO PCT/EP2016/067465 patent/WO2017013230A1/en not_active Ceased
- 2016-07-21 DK DK16744353.0T patent/DK3325509T3/da active
- 2016-07-21 HR HRP20210393TT patent/HRP20210393T1/hr unknown
- 2016-07-21 ES ES16744353T patent/ES2860988T3/es active Active
- 2016-07-21 RU RU2018106364A patent/RU2737637C2/ru active
- 2016-07-21 US US15/746,590 patent/US11230605B2/en active Active
- 2016-07-21 RS RS20210280A patent/RS61586B1/sr unknown
- 2016-07-21 CN CN201680040714.2A patent/CN107849136B/zh active Active
-
2021
- 2021-03-09 CY CY20211100200T patent/CY1123941T1/el unknown
- 2021-12-09 US US17/546,208 patent/US12037408B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12037408B2 (en) | Method of treating a tumor using anti-TfR antibodies | |
| AU2020286284B2 (en) | Novel anti-CD39 antibodies | |
| CN112512581B (zh) | 针对cldn18.2和cd3的抗体构建体 | |
| CN112867507B (zh) | 新型抗sirpa抗体 | |
| EP2760891B1 (en) | Hybrid constant regions | |
| KR102847971B1 (ko) | 항체-약물 컨쥬게이트 및 이의 암 치료 용도 | |
| KR20190083654A (ko) | Asct2에 특이적인 결합 분자 및 이의 용도 | |
| CN105873949A (zh) | 新的抗baff抗体 | |
| JP7419238B2 (ja) | Ｐｄ１結合剤 | |
| CN114981301B (zh) | Pd1和vegfr2双结合剂 | |
| CN116323671A (zh) | 具有增加的选择性的多靶向性双特异性抗原结合分子 | |
| EP3131917A2 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
| CN115803062B (zh) | 滋养层细胞表面抗原2(trop-2)抗体 | |
| CN117881699A (zh) | 抗SIRPα抗体 | |
| JP6853392B2 (ja) | 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物 | |
| HK1256088B (en) | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders | |
| BR112018000650B1 (pt) | Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios | |
| AU2023361530A1 (en) | Vegf antibodies |